Call for Papers: Applications of Next Generation CRISPR-Derived Technologies: Due date for submissions: August 1, 2020.

Graph: hum.2020.29106.cfp6 figure1.jpg CRISPR-based genome editing has revolutionized experimental biology and is being harnessed for human gene therapy. While initial applications of the CRISPR-Cas system were primarily based on the Cas9 endonuclease function, protein engineering has enabled a variety of other DNA- and RNA-altering functions to be guided by the Cas-sgRNA mechanism. I Human Gene Therapy i is now seeking original papers and review articles that describe the design, optimization, and application of these next-generation CRISPR approaches, including, but not limited to, the following technologies: Base editing Epigenome editing CRISPR-transactivation RNA editing Prime editing Anti-CRISPR proteins Novel Cas-based fusion proteins that confer novel functions, sequence-targeted by Cas-sgRNA Demonstrations of the utility of one or more of such technologies in animal models of specific human diseases, including monogenic disorders, is of particular interest. [Extracted from the article]